HLA-B*1502 screening and toxic effects of carbamazepine.

n engl j med 365;7 nejm.org august 18, 2011 672 receptor antibody, although the difference was not significant (P = 0.09). The necessity of the use of T-cell–depleting antibody versus non–T-cell– depleting antibody was therefore still in question when our study was designed in 2004. To our knowledge, our study is the only multicenter trial providing evidence that supports the use of T-cell– depleting antibody over interleukin-2–receptor antibody in patients with early corticosteroid withdrawal. Of note, the superiority claim for our study was restricted to early acute rejection, not long-term renal allograft function and survival. Michael J. Hanaway, M.D.